Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O5TR
|
|||
| Former ID |
DIB011031
|
|||
| Drug Name |
RBP-7000
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Application submitted | [2] | ||
| Company |
Reckitt benckiser pharmaceutical
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02109562) Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.